VBI Vaccines (NASDAQ:VBIV) Now Covered by Analysts at Raymond James

Raymond James initiated coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a report published on Thursday morning, The Fly reports. The brokerage issued an outperform rating and a $3.00 target price on the biopharmaceutical company’s stock.

A number of other equities research analysts have also issued reports on VBIV. ValuEngine raised shares of VBI Vaccines from a hold rating to a buy rating in a report on Thursday, August 1st. Zacks Investment Research lowered shares of VBI Vaccines from a buy rating to a hold rating in a research note on Wednesday, August 21st. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. VBI Vaccines currently has a consensus rating of Buy and a consensus target price of $3.81.

NASDAQ:VBIV traded up $0.03 during trading hours on Thursday, hitting $0.59. The stock had a trading volume of 2,507,500 shares, compared to its average volume of 2,156,749. The firm has a market capitalization of $100.25 million, a price-to-earnings ratio of -0.61 and a beta of 0.52. VBI Vaccines has a one year low of $0.47 and a one year high of $2.20. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.88 and a quick ratio of 1.84. The company has a 50 day simple moving average of $0.55 and a two-hundred day simple moving average of $1.00.

VBI Vaccines (NASDAQ:VBIV) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). The firm had revenue of $0.65 million during the quarter, compared to the consensus estimate of $0.90 million. VBI Vaccines had a negative return on equity of 70.54% and a negative net margin of 1,458.97%. Equities research analysts anticipate that VBI Vaccines will post -0.47 earnings per share for the current year.

In related news, Director Steven Gillis bought 10,000,000 shares of the business’s stock in a transaction dated Thursday, September 19th. The shares were purchased at an average price of $0.50 per share, with a total value of $5,000,000.00. Also, major shareholder Perceptive Advisors Llc bought 20,000,000 shares of the business’s stock in a transaction dated Monday, September 23rd. The shares were bought at an average cost of $0.50 per share, for a total transaction of $10,000,000.00. The disclosure for this purchase can be found here. Insiders have bought a total of 30,212,000 shares of company stock worth $15,105,440 in the last ninety days. Insiders own 10.50% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. General American Investors Co. Inc. boosted its stake in VBI Vaccines by 23.2% during the second quarter. General American Investors Co. Inc. now owns 2,174,264 shares of the biopharmaceutical company’s stock worth $2,544,000 after acquiring an additional 409,800 shares in the last quarter. JPMorgan Chase & Co. bought a new stake in VBI Vaccines during the second quarter worth about $25,000. Bank of Montreal Can boosted its stake in VBI Vaccines by 71.8% during the second quarter. Bank of Montreal Can now owns 37,604 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 15,717 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in VBI Vaccines by 664.5% during the second quarter. Charles Schwab Investment Management Inc. now owns 200,848 shares of the biopharmaceutical company’s stock worth $235,000 after acquiring an additional 174,576 shares in the last quarter. Finally, Fosun International Ltd boosted its stake in VBI Vaccines by 43.6% during the second quarter. Fosun International Ltd now owns 1,051,126 shares of the biopharmaceutical company’s stock worth $1,156,000 after acquiring an additional 319,045 shares in the last quarter. 26.55% of the stock is currently owned by hedge funds and other institutional investors.

About VBI Vaccines

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.

See Also: What is Depreciation?

The Fly

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.